Cost-effectiveness of teduglutide in adult patients with short bowel syndrome – a European socioeconomic perspective

• DOI: 10.1016/j.ajcnut.2024.02.031
• Publication Date: 2024-03-01T10:10:18Z
• Authors: Evelyn Walter; Christopher Dawoud; Elisabeth Hütterer; Anton Stift; Felix Harpain
• Keywords: Short Bowel Syndrome

The short bowel syndrome with intestinal failure (SBS-IF) is a rare but devastating medical condition. An absolute loss of length forces the patients into parenteral support (PS) dependency and variety sequalae resulting in increased morbidity mortality. Interdisciplinary treatment may include therapy effective, expensive intestinotrophic peptide teduglutide. A time-discrete Markov-model was developed to simulate effect (lifetime-costs, quality-adjusted life-years (QALYs) (LYs)) teduglutide plus best supportive care (BSC) compared BSC alone SBS-IF patients. health states model were structured around number days on PS. Clinical data from three sets used: (1) an Austrian observational study (base case) (2) pooled cohort studies (3) prospective STEPS studies. Direct indirect costs derived published sources. QALYs, LYs discounted (3% per annum). Under base case assumption associated 2,296,311 € patient 10.78 QALYs (13.74 LYs) over lifetime horizon. No 1,236,816 2.24 (8.57 LYs). incremental cost-utility ratio (ICUR) amounts 123,945 €. In clinical set, ICUR increases 184,961 If based used, 235,612 Teduglutide treating meets traditional cost-effectiveness criteria European societal perspective. Nevertheless, varying levels efficacy leave degree uncertainty calculations.